Angina pectoris Circulatory System Angina pectoris
Conditions
Interventions
Participants with chronic stable angina pectoris who are being treated with IMPLICOR® according to physicians assessment and the Summary of Product Characteristic (recommended dose: twice a day one ta
Sponsors
Servier Deutschland GmbH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or over 2. Ambulatory patients with chronic stable angina pectoris, who are treated according to the indication of IMPLICOR®. 3. Patients who were treated with free combination of active substances and who were controlled with equivalent doses of the free combination. 4. Patients with or without concomitant diseases
Exclusion criteria
Exclusion criteria: 1. Less than 18 years of age 2. Patients with contraindications to IMPLICOR®
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Influence of IMPLICOR® therapy on heart rate at each visit measured at baseline, 1 month and 4 months 2. Influence of IMPLICOR® therapy on number of angina attacks at each visit measured at baseline, 1 month and 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Influence of IMPLICOR® therapy on use of short-acting nitrates measured at baseline, 1 month and 4 months 2. Influence of IMPLICOR® therapy on symptomatic classification (CCS-class) by physicians' assessment measured at baseline and 4 months 3. Influence of IMPLICOR® therapy on hospitalization rate measured at baseline and 4 months 4. Influence of IMPLICOR® therapy on patients’ compliance/adherence measured at baseline and 4 months 5. Adding of knowledge regarding general tolerance and specific adverse drug reactions (ADR) under IMPLICOR® therapy by standardized questionnaire measured at 1 month and 4 months 6. General assessment of IMPLICOR® therapy in symptomatic patients with angina pectoris by physician measured at 4 months | — |
Countries
Germany
Outcome results
None listed